These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 17457997)

  • 1. New HIV drug classes on the horizon.
    Opar A
    Nat Rev Drug Discov; 2007 Apr; 6(4):258-9. PubMed ID: 17457997
    [No Abstract]   [Full Text] [Related]  

  • 2. HIV entry inhibitors: progress in development and application.
    Lai WH; Huang L; Chen CH
    Yao Xue Xue Bao; 2010 Feb; 45(2):131-40. PubMed ID: 21348414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in HIV-1 tropism: clinical and prognostic consequences.
    Mosier DE
    Eur J Med Res; 2007 Oct; 12(9):371-4. PubMed ID: 17933716
    [No Abstract]   [Full Text] [Related]  

  • 4. Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients.
    Schapiro JM; Boucher CA; Kuritzkes DR; van de Vijver DA; Llibre JM; Lewis M; Simpson P; Delogne C; McFadyen L; Chapman D; Perros M; Valdez H; van der Ryst E; Westby M
    Antivir Ther; 2011; 16(3):395-404. PubMed ID: 21555822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA notifications. Maraviroc approved as a CCR5 co-receptor antagonist.
    AIDS Alert; 2007 Sep; 22(9):103. PubMed ID: 18411462
    [No Abstract]   [Full Text] [Related]  

  • 6. Novel CCR5 antagonists for the treatment of HIV infection: a review of compounds patented in 2006 - 2008.
    Yang H; Rotstein DM
    Expert Opin Ther Pat; 2010 Mar; 20(3):325-54. PubMed ID: 20180619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Something new under the sun. Maraviroc poised for approval.
    Huff B
    GMHC Treat Issues; 2006; 20(8-12):1-4. PubMed ID: 17569160
    [No Abstract]   [Full Text] [Related]  

  • 8. Baseline susceptibility of primary HIV-2 to entry inhibitors.
    Borrego P; Calado R; Marcelino JM; Bártolo I; Rocha C; Cavaco-Silva P; Doroana M; Antunes F; Maltez F; Caixas U; Barroso H; Taveira N
    Antivir Ther; 2012; 17(3):565-70. PubMed ID: 22293827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-HIV agents. Getting to know your co-receptors.
    TreatmentUpdate; 2007; 19(3):1-2. PubMed ID: 17571439
    [No Abstract]   [Full Text] [Related]  

  • 10. Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents.
    MacArthur RD; Novak RM
    Clin Infect Dis; 2008 Jul; 47(2):236-41. PubMed ID: 18532888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. When and how to use maraviroc in HIV-infected patients.
    Soriano V; Perno CF; Kaiser R; Calvez V; Gatell JM; di Perri G; Pillay D; Rockstroh J; Geretti AM
    AIDS; 2009 Nov; 23(18):2377-85. PubMed ID: 19834318
    [No Abstract]   [Full Text] [Related]  

  • 12. Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1.
    Hunt JS; Romanelli F
    Pharmacotherapy; 2009 Mar; 29(3):295-304. PubMed ID: 19249948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First medication in new class of ARTs poised to be available for salvage therapy. Tropism testing helps determine best patients for drug.
    AIDS Alert; 2007 Aug; 22(8):85-8. PubMed ID: 17763555
    [No Abstract]   [Full Text] [Related]  

  • 14. Two new drugs for HIV infection.
    Med Lett Drugs Ther; 2008 Jan; 50(1277):2-4. PubMed ID: 18197163
    [No Abstract]   [Full Text] [Related]  

  • 15. T-cell changes after a short-term exposure to maraviroc in HIV-infected patients are related to antiviral activity.
    Pulido I; Machmach K; Romero-Sánchez MC; Genebat M; Mendez-Lagares G; Ruiz-Mateos E; Leal M
    J Infect; 2012 Apr; 64(4):417-23. PubMed ID: 22227467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-2 susceptibility to entry inhibitors.
    Borrego P; Taveira N
    AIDS Rev; 2013; 15(1):49-61. PubMed ID: 23449229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-HIV agents. Maraviroc--absorption and drug-interaction issues.
    TreatmentUpdate; 2007; 19(3):5. PubMed ID: 17571441
    [No Abstract]   [Full Text] [Related]  

  • 18. Maraviroc (Celsentri) for multidrug-resistant human immunodeficiency virus (HIV)-1.
    Ndegwa S
    Issues Emerg Health Technol; 2007 Dec; (110):1-8. PubMed ID: 18080399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Report from the XVI International HIV Drug Resistance Workshop.
    Kuritzkes DR
    AIDS Clin Care; 2007 Aug; 19(8):69-70. PubMed ID: 17695089
    [No Abstract]   [Full Text] [Related]  

  • 20. Maraviroc: a new CCR5 antagonist.
    Sayana S; Khanlou H
    Expert Rev Anti Infect Ther; 2009 Feb; 7(1):9-19. PubMed ID: 19622053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.